Concomitant application with CTLA or PD-1 therapies not only impedes HNSCC progression and mitigates autoimmune-like manifestations but also enhances the cytotoxicity against CAFs and fosters dendritic cell maturation following splenic uptake [105,107]. This evidence concerns the gene RPL17 and head and neck squamous cell carcinoma.